Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05938725 · ClinicalTrials.gov registry record · Phase 1
KYSA-1: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis
A Phase 1 study of Lupus Nephritis and Lupus Nephritis - WHO Class IV, sponsored by Kyverna Therapeutics.
- Active
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
- 6
- Study locations
NCT05938725 is a Phase 1 study of Lupus Nephritis and Lupus Nephritis - WHO Class IV that is active but no longer recruiting, run by Kyverna Therapeutics. The registered enrollment target is 6 participants, below the 310-participant average among 30 other Lupus Nephritis trials with a reported enrollment target (98% lower). The trial reports 6 study locations across 6 states.
The verdict
NCT05938725, a Phase 1 study of Lupus Nephritis and Lupus Nephritis - WHO Class IV, is active but no longer recruiting, sponsored by Kyverna Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
- 6
- Study locations
Study Summary
A Study of Anti-CD19 Chimeric Antigen Receptor T Cell Therapy for Subjects With Refractory Lupus Nephritis
Conditions Studied
Interventions
- BIOLOGICAL KYV-101 anti-CD19 CAR-T cell therapy
- DRUG Standard lymphodepletion regimen
Study Locations (6)
California
- Stanford University Medical Center - Palo Alto
Colorado
- University of Colorado - Denver
Massachusetts
- University of Massachusetts Worcester - Worcester
New York
- Northwell Health - Great Neck
Ohio
- Ohio State University Wexner Medical Center - Columbus
Pennsylvania
- University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2023-04-28 |
| Est. Completion | 2027-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05938725
The ClinicalTrials.gov registry entry for NCT05938725 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 310-participant average among 30 other Lupus Nephritis trials with a reported enrollment target (98% lower). The listed sponsor is Kyverna Therapeutics, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Lupus Nephritis appearing as the primary indexed condition, and to 2 interventions - of which KYV-101 anti-CD19 CAR-T cell therapy is the first listed.
NCT05938725 reports 6 study locations spanning 6 distinct geographic areas - top geographies include California, Colorado, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05938725 about?
NCT05938725 is a clinical study titled "KYSA-1: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis". A Study of Anti-CD19 Chimeric Antigen Receptor T Cell Therapy for Subjects With Refractory Lupus Nephritis
What is the current status of trial NCT05938725?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2023-04-28. Estimated completion is 2027-08.
What conditions does trial NCT05938725 study?
This clinical trial studies the following conditions: Lupus Nephritis, Lupus Nephritis - WHO Class IV, Lupus Nephritis - World Health Organization (WHO) Class III.
What interventions are being tested in trial NCT05938725?
The interventions under investigation include: KYV-101 anti-CD19 CAR-T cell therapy (BIOLOGICAL), Standard lymphodepletion regimen (DRUG).
Who is sponsoring clinical trial NCT05938725?
This trial is sponsored by Kyverna Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05938725 being conducted?
This trial has 6 study locations across California, Colorado, Massachusetts, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lupus Nephritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
RECRUITING · Phase 1
-
Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders
RECRUITING · Phase 1
-
A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1)
RECRUITING · Phase 1
-
RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
RECRUITING · Phase 1
-
A Study to Learn More About the Safety and Effects of Felzartamab in Adults With Lupus Nephritis Aged 18 to 75 Years Old
ACTIVE NOT RECRUITING · Phase 1
-
A Study of CNTY-101 in Participants With Refractory B Cell-mediated Autoimmune Diseases
ACTIVE NOT RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.